And this…
Plandai Biotechnology, Inc. Announces Phytofare(TM) Catechin Complex Shows Over Two Times the Level of Catechins Compared to Generic Extract
Test Results Help Validate Plandai’s Extraction Process
SEATTLE, WA, Jun 24, 2014 (Marketwired via COMTEX) — Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has received test results from North-West University that indicate that Plandai’s Phytofare(TM) Catechin Complex, which is derived from green tea phyto-nutrients, contains 2.2 times the amount of catechins by weight when compared to generic green tea extracts.
The testing, conducted by Prof. Anne Grobler, the Director of Preclinical Platform, Department of Pharmacology with North-West University in Potchefstroom, South Africa, included a full chemical profile. The results showed that Phytofare(TM) Catechin Complex contained between 80-88% catechins by weight, compared to around 40% in the generic samples. As with the generic extracts, the dominant catechin in Phytofare(TM) Catechin Complex is EGCG (epigallocatechin-3-gallate), which has been the subject of numerous investigative studies testing its potential use as a therapeutic for a broad range of applications including HIV, cancers, malaria, neuro-degradation diseases, weight loss, and anti-aging.
Vice President of Sales Callum Baylis-Duffield commented, “While the increased level of catechins should not be confused with increased bioavailability, it does show that our live-plant extraction process is more efficient. The testing conducted by North-West University affirms our belief that the extraction methodology involved in producing Phytofare yields a superior finished product, which we believe will demonstrate superior clinical results. Further refinements to the system, as we draw closer to commercial production, should help us push that efficiency even higher towards our goal of 95% catechin purity by weight.”